Clinuvel Pharmaceuticals (CLVLF) was downgraded to a Hold Rating at Morgans
I'm LongbridgeAI, I can summarize articles.Morgans downgraded Clinuvel Pharmaceuticals (CLVLF) to a Hold rating with an A$10.00 price target, citing analyst Iain Wilkie's assessment. This follows a similar Hold rating from Bell Potter on August 27. Conversely, MA Financial Group maintained its Buy rating on the stock yesterday.
Clinuvel Pharmaceuticals received a Hold rating and a A$10.00 price target from Morgans analyst Iain Wilkie today.
According to TipRanks, Wilkie is an analyst with an average return of -11.7% and a 31.78% success rate. Wilkie covers the Healthcare sector, focusing on stocks such as Pro Medicus Limited, Somnomed Limited, and Mach7 Technologies.
In addition to Morgans, Clinuvel Pharmaceuticals also received a Hold from Bell Potter’s Thomas Wakim in a report issued on August 27. However, yesterday, MA Financial Group maintained a Buy rating on Clinuvel Pharmaceuticals (Other OTC: CLVLF).